Actinium Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Actinium Pharmaceuticals, Inc. on May 31, 2013. The filing reports the termination of a material consulting agreement and the resignation of a director, Dr. Rosemary Mazanet, effective as of the report date.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to a settlement payment of $25,000 made to Dr. Mazanet in full satisfaction of amounts owed under the terminated Consulting Agreement.
Material Changes
- Termination of Agreement: The Consulting Services Agreement dated January 4, 2012, between the Company and Dr. Mazanet was terminated by mutual agreement with no early termination penalties.
- Director Resignation: Dr. Rosemary Mazanet resigned as a director of Actinium Pharmaceuticals, Inc. and its subsidiary, Actinium Corporation, to pursue other opportunities. The resignation was not based on any disagreement with the Company regarding operations, policies, or practices.
- Compensatory Arrangement: In addition to the $25,000 cash payment, Dr. Mazanet is entitled to 83,250 vested Company options exercisable until the ten-year anniversary of their respective grants.
Outlook, Risks, and Unusual Items
The filing includes standard mutual releases, non-disparagement clauses, and a non-solicitation provision as part of the separation agreement. Dr. Mazanet agreed to a lock-up provision, agreeing not to sell or transfer shares underlying the options or other Company securities until the earlier of twelve months from December 28, 2012, or six months following the effective date of the Registration Statement filed on March 15, 2013. No forward-looking guidance or new risk factors were disclosed in this report.
Key Facts for Investor Verification
- Verify the impact of the $25,000 cash settlement on the Company's current liquidity position.
- Confirm the status of the 83,250 vested options granted to the departing director and their potential dilution effect.
- Review the Company's recent Registration Statement filed on March 15, 2013, to understand the context of the lock-up agreement.
- Assess the Company's current board composition following the resignation of Dr. Mazanet.